Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -82.7%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22M | $96M | $11.0B | $135M | $170M | $246M | $25M | $13M | $1M | $4M | $4M |
| Enterprise Value | $-73633015 | $126060 | $10.9B | $14M | $-31223560 | $13M | $-67778899 | $-10055625 | $-18510205 | $-6743758 | $-12898762 |
| P/E Ratio → | -0.52 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.29 | 1.29 | 75.49 | 0.98 | 0.75 | 0.97 | 0.28 | 0.59 | 0.07 | 0.39 | 0.20 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.7% | -82.7% | -17.2% | -53.3% | -31.7% | -18.7% | -11.1% | -22.2% | -44.7% | -84.1% | -79.7% |
| ROA | -65.9% | -65.9% | -15.7% | -50.3% | -30.4% | -17.9% | -10.8% | -21.2% | -42.3% | -79.1% | -76.9% |
| ROIC | — | — | -634.1% | -369.7% | -253.4% | -250.3% | — | — | — | -1443.1% | — |
| ROCE | -86.6% | -86.6% | -99.9% | -58.0% | -33.2% | -19.0% | -19.3% | -46.4% | -45.4% | -84.3% | -80.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.28 | -0.88 | -0.88 | -0.88 | -0.92 | -1.01 | -1.04 | -1.01 | -1.08 | -0.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($96M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.23 | 2.23 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 |
| Quick Ratio | 2.23 | 2.23 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 |
| Cash Ratio | 2.18 | 2.18 | 10.94 | 8.53 | 28.46 | 18.62 | 50.14 | 16.64 | 38.76 | 9.26 | 28.14 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $48M | $4.7B | $42M | $40M | $39M | $26M | $17M | $11M | $7M | $7M |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FLNA stock.
Filana Therapeutics, Inc.'s current P/E ratio is -0.5x. The historical average is 4.0x.
Filana Therapeutics, Inc.'s return on equity (ROE) is -82.7%. The historical average is -24.4%.
Based on historical data, Filana Therapeutics, Inc. is trading at a P/E of -0.5x. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Clinical trial binary outcome
Metrics are mathematically derived from official filings.
Controversy Discount Compresses Market Valuation
As reported in recent financial statements, the company's P/B ratio of 0.42 suggests a significant market discount, likely reflecting investor skepticism regarding clinical data integrity and the high probability of future dilutive financing requirements compared to peers like ACADIA Pharmaceuticals which trade at higher multiples.
The current valuation appears to be driven more by the binary risk of Phase 3 trial outcomes than by traditional fundamental metrics. Investors should monitor whether this discount persists as the company approaches data readouts, as a successful trial could trigger a rapid re-rating of the stock.
Negative Returns Reflect Development Phase
Based on historical data, the company's ROIC has remained deeply negative, reaching -134.5% in 2025Q1, which is consistent with a pre-revenue biotech firm that is currently consuming capital to fund R&D rather than generating returns on invested capital through commercial operations.
The persistent decay in ROIC highlights the lack of operational efficiency inherent in the current business model. Until the company transitions to a commercial stage, these metrics will likely remain distorted by the heavy reliance on external capital to sustain clinical development.
Liquidity Buffer Facing Persistent Compression
According to recent quarterly filings, the current ratio has compressed from a peak of 11.62 in 2024Q4 to 2.27 in 2025Q3, indicating that the company's immediate liquidity buffer is narrowing as cash reserves are depleted to support ongoing Phase 3 clinical trial activities and associated professional fees.
The rapid decline in the current ratio warrants close attention, as it suggests the company is approaching a point where additional capital may be required to maintain operations. Investors should consider the potential for further dilution if the current cash runway is insufficient to reach key clinical milestones.
Misapplication of Traditional Valuation Multiples
As noted in institutional research, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for a pre-revenue clinical-stage biotech like SAVA, as these metrics obscure the company's reliance on binary clinical trial outcomes rather than recurring cash flows or operational profitability.
Analysts should instead focus on cash runway and the probability-weighted net present value of the lead therapeutic candidate, Simufilam. Relying on traditional valuation multiples may lead to an inaccurate assessment of the company's true risk-reward profile, which is inherently tied to regulatory and clinical success.